Pharmerging Market: By Geography (Tier I Countries (China), Tier II Countries (Brazil, India, Russia), Tier III Countries(Poland, Argentina, Turkey, Mexico, Venezuela, South Africa, Algeria, Pakistan, Nigeria, Ukraine)) & Geography - Forecast(2018 - 2023)

Report Code : HCR 0310 Format Type: PDF+ Excel Database

Globally, growing global pharmaceutical market, rise in public and private healthcare insurance, rise in collaboration, and mergers and acquisitions among multinationals rise in the awareness among people regarding pharmerging, and increasing government initiative across the globe, are the prime growth drivers of global pharmerging market. In addition, increase in adoption of pharmerging in emerging economies such as China, India and others, will create new opportunities for global pharmerging market. However, higher cost of the research and development, and complex government approval process, are the key restraints for global pharmerging market.

 Pharmerging Market

Geographically, pharmerging markets
are defined as those countries having a per capita GDP threshold of USD 25,000 and more than USD one billion spending growth from 2012 to 2016.  Thus, the pharmerging markets includes 21 countries which are further categorized in Tier I, Tier II, Tier III countries based on the IMS defined parameters and the macroeconomic factors and respective pharmaceutical market forecasts. Tier I countries which includes China, dominated global pharmerging market because of higher Chinese government’s healthcare spending. However, Tier II countries which includes India, Brazil and Russia are project to grow significantly, owing to rapidly increasing aging population, rise in consumer awareness, favourable government policies, and modernization of healthcare infrastructure in this countries. The presence of numerous small and large vendors has made the pharmerging markets highly fragmented. Challenges such as price pressure, regulatory constraints, and competition from local and other international pharmaceutical companies are faced by most of the international pharmaceutical companies. Majority of pharmaceuticals giants are focusing on technological innovations, product extensions, and inorganic growth through mergers and acquisitions, which would intensify the market in near future.

This report identifies the global pharmerging market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to global pharmerging market.

This report segments global pharmerging market on the basis of geography market as follows:
  • This report has been segmented into major geography market of pharmerging, such as: Tier I Countries (China), Tier II Countries (Brazil, India, and Russia), and Tier III Countries (Poland, Argentina, Turkey, Mexico, Venezuela, Romania, Saudi Arabia, Colombia, Vietnam, South Africa, Algeria, Thailand, Indonesia, Egypt, Pakistan, Nigeria, and Ukraine)

This report identifies all the major companies operating in the pharmerging market. Some of the major companies’ profiles in detail are as follows:
  • Merck & Co Inc.
  • Novartis International AG
  • Bristol-Myers Squibb Co
  • Boehringer Ingelheim Pharmaceuticals Corporation
  • Eli Lilly and Co.


Request Sample Data